DMAAR vs KLAC · $1.8M cap vs P/E 55, rev $13.58B
Drugs Made In America Acquisition Corp. Rights (DMAAR) versus KLA Corporation (KLAC) — a side-by-side from cached financials, not a winner call.
Drugs Made In America Acquisition Corp. Rights (DMAAR) common stock listed on US.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
DMAAR does not have a complete income-statement cache yet.
Latest reported KLAC revenue for 2026-06-30 was $13.58B. Net income was $4.83B. Revenue was up 11.7% from 2025-06-30 to 2026-06-30. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
DMAAR currently screens at market cap $1.8M. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Not investment advice. Open the DMAAR and KLAC stock pages for the full models.
Not investment advice.